MA42985A - Traitement de troubles liés à l'acide biliaire - Google Patents

Traitement de troubles liés à l'acide biliaire

Info

Publication number
MA42985A
MA42985A MA042985A MA42985A MA42985A MA 42985 A MA42985 A MA 42985A MA 042985 A MA042985 A MA 042985A MA 42985 A MA42985 A MA 42985A MA 42985 A MA42985 A MA 42985A
Authority
MA
Morocco
Prior art keywords
treatment
related disorders
biliary acid
biliary
acid
Prior art date
Application number
MA042985A
Other languages
English (en)
Inventor
Mei-Hsiu M Chen
Clarence H Hale
Shanaka Stanislaus
Murielle Veniant-Ellison
Jing Xu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA42985A publication Critical patent/MA42985A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA042985A 2015-10-01 2016-09-30 Traitement de troubles liés à l'acide biliaire MA42985A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562236050P 2015-10-01 2015-10-01

Publications (1)

Publication Number Publication Date
MA42985A true MA42985A (fr) 2018-08-22

Family

ID=57145043

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042985A MA42985A (fr) 2015-10-01 2016-09-30 Traitement de troubles liés à l'acide biliaire

Country Status (8)

Country Link
US (1) US20180280474A1 (fr)
EP (1) EP3355908A1 (fr)
JP (1) JP2018529729A (fr)
AU (1) AU2016332062A1 (fr)
CA (1) CA3000697A1 (fr)
MA (1) MA42985A (fr)
MX (1) MX2018004041A (fr)
WO (1) WO2017059371A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108570109B (zh) 2017-03-14 2022-04-26 广东东阳光药业有限公司 包含免疫球蛋白Fc部分的双靶点融合蛋白
AU2019218147B2 (en) 2018-02-08 2023-06-08 Sunshine Lake Pharma Co., Ltd. FGF21 variant, fusion protein and application thereof
US11427623B1 (en) 2019-05-28 2022-08-30 89Bio Ltd. Methods of treatment using mutant FGF-21 peptide conjugates
WO2021139763A1 (fr) * 2020-01-08 2021-07-15 上海翰森生物医药科技有限公司 Protéine mutante fgf21 et protéine de fusion correspondante
CN115322794B (zh) 2020-01-11 2025-09-19 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
CA3224743A1 (fr) 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Polypeptides de fusion pour troubles metaboliques
AU2022341345A1 (en) * 2021-09-08 2024-03-28 Leto Laboratories Co., Ltd Fgf21 mutant protein and use thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0154316B1 (fr) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Lymphokine chimiquement modifiée et son procédé de préparation
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
DE3889853D1 (de) 1987-11-05 1994-07-07 Hybritech Inc Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP0822830B1 (fr) 1995-04-27 2008-04-02 Amgen Fremont Inc. Anticorps anti-IL-8 dérivés de xenosouris immunisées
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
SMT202400036T1 (it) * 2009-05-05 2024-03-13 Amgen Inc Mutanti fgf21 e loro utilizzi
US20120052069A1 (en) * 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
CA2845357A1 (fr) * 2011-08-31 2013-03-07 Amgen Inc. Procede de traitement ou d'amelioration du diabete de type i employant fgf21
SG11201504815QA (en) * 2012-12-27 2015-07-30 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases

Also Published As

Publication number Publication date
WO2017059371A1 (fr) 2017-04-06
AU2016332062A1 (en) 2018-04-26
EP3355908A1 (fr) 2018-08-08
JP2018529729A (ja) 2018-10-11
MX2018004041A (es) 2018-11-09
CA3000697A1 (fr) 2017-04-06
US20180280474A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
MA45192A (fr) Traitement d'association
EP3765960A4 (fr) Traitement de flux d'événements
EP3491149A4 (fr) Traitement d'acide nucléique indépendant
EP3370721A4 (fr) Traitement de l'ostéoarthrite
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
MA42985A (fr) Traitement de troubles liés à l'acide biliaire
EP3558313A4 (fr) Substances pour le traitement d'affections liées à la stéatose hépatique
EP3340982A4 (fr) Composés pour le traitement de troubles immunitaires et inflammatoires
EP3500267A4 (fr) Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles neurodégénératifs
MA40867A (fr) Méthodes pour le traitement d'infections virales à filoviridae
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
EP3331527A4 (fr) Procédés de traitement de troubles du développement à l'aide de pipradrol
EP3340971A4 (fr) Méthodes de traitement de syndrome de lennox-gastaut à l'aide de fenfluramine
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
MA44737A (fr) Compositions pour le traitement de troubles liés à l'hyperkératose
EP3503904A4 (fr) Traitement par ascaroside de l'oesophagite à éosinophiles
EP3423100A4 (fr) Compositions destinées à traiter l'inflammation et méthodes de traitement associées
EP3362065A4 (fr) Polythérapie pour le traitement de malignités
EP3328864A4 (fr) Composés et compositions thérapeutiques pour le traitement de troubles sociaux et de troubles liés à la toxicomanie
EP3405183A4 (fr) Dérivés d'adamatane pour le traitement d'une infection à filovirus
EP3352749A4 (fr) Composés et compositions pour le traitement de troubles oculaires
EP3454793A4 (fr) Bobines de traitement d'anévrisme
EP3344325A4 (fr) Administration locale de médicaments pour le traitement de l'asthme
EP3347032A4 (fr) Traitement de l'ascite
MA43106A (fr) Traitement de l'oligo-ovulation associée à la stéatose hepatique